MetaADEDB 2.0 @ LMMD
Lotrimin Ultra
(STWJOZUHSWUDPQ-UHFFFAOYSA-N)
Structure
SMILES
CN(c1cccc2c1cccc2)Cc1ccc(cc1)C(C)(C)C.Cl
Molecular Formula:
C22H26ClN
Molecular Weight:
339.902
Log P:
6.5757
Hydrogen Bond Acceptor:
1
Hydrogen Bond Donor:
1
TPSA:
3.24
CAS Number(s):
N/A
Synonym(s)
1.
Lotrimin Ultra
External Link(s)
PubChem Compound83888
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Drug ineffectiveFAERS: 89US FAERS
2Product use issueFAERS: 22US FAERS
3Product use in unapproved indicationFAERS: 15US FAERS
4PruritusFAERS: 14US FAERS
5Drug ineffective for unapproved indicationFAERS: 13US FAERS
6ErythemaFAERS: 9US FAERS
7Skin irritationFAERS: 8US FAERS
8Drug administered at inappropriate siteFAERS: 6US FAERS
9Circumstance or information capable of leading to medication errorFAERS: 5US FAERS
10Drug administered to patient of inappropriate ageFAERS: 5US FAERS
11Incorrect drug administration durationFAERS: 5US FAERS
12PainFAERS: 5US FAERS
13Application site erythemaFAERS: 4US FAERS
14Application site painFAERS: 4US FAERS
15Burning sensationFAERS: 4US FAERS
16Drug prescribing errorFAERS: 4US FAERS
17Expired product administeredFAERS: 4US FAERS
18HypersensitivityFAERS: 4US FAERS
19Inappropriate schedule of drug administrationFAERS: 4US FAERS
20Product administered at inappropriate siteFAERS: 4US FAERS
21Therapeutic response unexpectedFAERS: 4US FAERS
22Unevaluable eventFAERS: 4US FAERS
23Wrong technique in product usage processFAERS: 4US FAERS
24Peripheral swellingFAERS: 3US FAERS
25Product quality issueFAERS: 3US FAERS
26Rash erythematousFAERS: 3US FAERS
27UrticariaFAERS: 3US FAERS
28Accidental exposure to productFAERS: 2US FAERS
29DiscomfortFAERS: 2US FAERS
30DizzinessFAERS: 2US FAERS
31Drug effect incompleteFAERS: 2US FAERS
32Drug effective for unapproved indicationFAERS: 2US FAERS
33Expired drug administeredFAERS: 2US FAERS
34NauseaFAERS: 2US FAERS
35Product label confusionFAERS: 2US FAERS
36Renal painFAERS: 2US FAERS
37skin abrasionFAERS: 2US FAERS
38Abdominal discomfortFAERS: 1US FAERS
39Accidental exposure to product by childFAERS: 1US FAERS
40AcneFAERS: 1US FAERS
41AnxietyFAERS: 1US FAERS
42Application site burnFAERS: 1US FAERS
43Application site reactionFAERS: 1US FAERS
44Application site warmthFAERS: 1US FAERS
45Chest PainFAERS: 1US FAERS
46Dry skinFAERS: 1US FAERS
47Exfoliative rashFAERS: 1US FAERS
48Feeling abnormalFAERS: 1US FAERS
49HeadacheFAERS: 1US FAERS
50Inappropriate schedule of product administrationFAERS: 1US FAERS
51Incorrect dose administeredFAERS: 1US FAERS
52Incorrect route of drug administrationFAERS: 1US FAERS
53InflammationFAERS: 1US FAERS
54Intentional product use issueFAERS: 1US FAERS
55MalaiseFAERS: 1US FAERS
56Medication ErrorFAERS: 1US FAERS
57NasopharyngitisFAERS: 1US FAERS
58Pain of skinFAERS: 1US FAERS
59PapuleFAERS: 1US FAERS
60Pelvic PainFAERS: 1US FAERS
61Poor quality drug administeredFAERS: 1US FAERS
62Product label issueFAERS: 1US FAERS
63Product lot number issueFAERS: 1US FAERS
64Product physical consistency issueFAERS: 1US FAERS
65Product prescribing issueFAERS: 1US FAERS
66Product selection errorFAERS: 1US FAERS
67Scrotal erythemaFAERS: 1US FAERS
68Skin ErosionFAERS: 1US FAERS
69SwellingFAERS: 1US FAERS
70Therapeutic product ineffectiveFAERS: 1US FAERS
71Therapeutic product ineffective for unapproved indicationFAERS: 1US FAERS
72Thermal burnFAERS: 1US FAERS
73Tinea crurisFAERS: 1US FAERS
74VomitingFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120263

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.